The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Merck; Tesaro/GSK
Research Funding - Agenus (Inst); Ambry Genetics (Inst); Celsion (Inst); Clovis Oncology (Inst); Genentech (Inst); ImmunoGen (Inst); Merck (Inst); Regeneron (Inst); Splash Pharmaceuticals (Inst); Takeda (Inst); Tesaro (Inst); VBL Therapeutics (Inst)
A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007.
 
Timothy A Yap
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex
Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)
Travel, Accommodations, Expenses - Atrin Pharmaceuticals; Calithera Biosciences; EMD Serono; Leidos Biomedical Research; Lilly; Pfizer; Tesaro
 
Mallika Sachdev Dhawan
No Relationships to Disclose
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Ipsen; Novartis; Perthera
Research Funding - Ipsen
Travel, Accommodations, Expenses - Halozyme
 
Michele Maio
Stock and Other Ownership Interests - Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Consulting or Advisory Role - Alfasigma; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Patents, Royalties, Other Intellectual Property - DNA Hypomethylating agents for cancer therapy
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
 
Taofeek Kunle Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; ARMO BioSciences; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; HERON; Lilly; Lilly; MedImmune; Merck; Novartis; PharmaMar; Sandoz; Seagen; Takeda; Xcovery
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; Fujifilm (Inst); G1 Therapeutics (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Miguel Quintela-Fandino
Consulting or Advisory Role - Bayer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); MEI Pharma (Inst); Novartis (Inst); Roche (Inst)
 
Roni Shapira
Consulting or Advisory Role - Clovis Oncology; Merck
 
Sanatan Saraf
Employment - Merck Sharp & Dohme
 
Ping Qiu
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Fan Jin
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck; Merck
 
Alexander Gozman
Employment - Merck Sharp & Dohme
 
Douglas A Levine
No Relationships to Disclose